RNA
Atrium Therapeutics, Inc. NASDAQ Listed Feb 27, 2026$9.22
Pre-mkt
$9.39
+1.84%
Mkt Cap $157.7M
52w Low $8.66
6.9% of range
52w High $16.77
50d MA $12.08
200d MA $12.88
P/E (TTM)
-2.1x
EV/EBITDA
—
P/B
0.8x
Debt/Equity
0.0x
ROE
-40.5%
P/FCF
-3.7x
RSI (14)
17.00
ATR (14)
$0.76
Beta
0.00
50d MA
$12.08
200d MA
$12.88
Avg Volume
309.5K
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
10578 Science Center Drive · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -1.24 | -0.61 | +50.8% | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 6 | H.C. Wainwright | Initiates | Buy | $25 | $11.74 | $11.96 | +1.9% | +3.2% | +1.9% | -0.8% | +0.2% | -0.8% |
| Jun 18 | Cantor Fitzgerald | Initiates | Overweight | $25 | $12.48 | $12.83 | +2.8% | +1.4% | +2.2% | -1.0% | +0.2% | -0.4% |
| May 15 | Leerink Partners | Initiates | Outperform | $25 | $13.27 | $13.48 | +1.6% | -0.3% | -2.1% | +0.0% | -1.8% | +2.5% |
| Nov 11 | Chardan Capital | Maintains | Neutral → Neutral | — | — | — | — | — | — | — | — | — |
| Oct 29 | TD Cowen | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Oct 28 | Chardan Capital | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Oct 28 | RBC Capital | Downgrade | Outperform → Sector Perform | — | — | — | — | — | — | — | — | — |
| Oct 27 | Needham | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Oct 27 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Oct 27 | Leerink Partners | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Oct 27 | Raymond James | Downgrade | Strong Buy → Market Perform | — | — | — | — | — | — | — | — | — |
| Oct 27 | Bernstein | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Oct 27 | Citigroup | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Sep 22 | Evercore ISI | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Sep 15 | BofA Securities | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 10 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 10 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 8 | Barclays | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Aug 8 | Wells Fargo | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Jun 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Jun 10 | Citigroup | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jun 10 | Barclays | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Jun 9 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jun 9 | BofA Securities | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 9 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 7 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Apr 9 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 17 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 17 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 10 | BofA Securities | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Feb 28 | Barclays | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Feb 28 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Nov 13 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Oct 31 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Oct 30 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Oct 21 | TD Cowen | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Sep 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Aug 26 | Evercore ISI | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Aug 13 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 12 | Evercore ISI | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
No insider trades available.
8-K
Atrium Therapeutics, Inc. -- 8-K Filing
Jul 14
8-K · 2.02
!! High
Atrium Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 14
8-K · 5.02
!!! Very High
Atrium Therapeutics, Inc. -- 8-K 5.02: Executive Change
Atrium Therapeutics appointed four new directors following its distribution from Bristol Myers Squibb, signaling completion of the planned spinoff and establishment of independent board governance.
Feb 27
8-K · 5.02
!!! Very High
Atrium Therapeutics, Inc. -- 8-K 5.02: Executive Change
Novartis's acquisition of Atrium Therapeutics closed at $72.00 per share, providing value to optionholders whose stock options exceeded the exercise price.
Feb 27
8-K
Atrium Therapeutics, Inc. -- 8-K Filing
Atrium Therapeutics completed a spin-off from its parent company, creating an independent entity focused on its therapeutic pipeline with separate ownership structure and operational autonomy.
Feb 26
8-K · 7.01
! Medium
Atrium Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Avidity Biosciences plans to distribute all Atrium Therapeutics shares pro rata to its stockholders, creating a spinoff that will give Avidity investors direct ownership in the independent company.
Feb 26
8-K
Atrium Therapeutics, Inc. -- 8-K Filing
Novartis's acquisition of Atrium Therapeutics (RNA) through Avidity Biosciences is progressing toward shareholder vote, with the definitive proxy statement filed January 30, 2026.
Feb 23
8-K
Atrium Therapeutics, Inc. -- 8-K Filing
This filing appears to contain standard forward-looking statement disclaimers rather than material news, providing limited actionable information for investors regarding Atrium Therapeutics' operations or financial condition.
Feb 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | 1,447,476 | $19M | New | Jun 2026 |
| 2 | Vanguard Capital Management Llc | 730,831 | $10M | Added | Jun 2026 |
| 3 | Two Sigma Investments, Lp | 345,481 | $5M | Added | Jun 2026 |
| 4 | Bellevue Group Ag | 263,096 | $4M | New | Mar 2026 |
| 5 | Arbiter Partners Capital Management Llc | 261,288 | $4M | Added | Jun 2026 |
| 6 | Millennium Management Llc | 200,559 | $3M | Added | Jun 2026 |
| 7 | Aqr Capital Management Llc | 172,235 | $2M | New | Jun 2026 |
| 8 | Marble Bar Asset Management Llp | 147,000 | $2M | New | Mar 2026 |
| 9 | Bracebridge Capital, Llc | 139,239 | $2M | New | Jun 2026 |
| 10 | Janus Henderson Group Plc | 139,973 | $2M | New | Mar 2026 |
| 11 | Nomura Holdings Inc | 137,380 | $2M | New | Mar 2026 |
| 12 | Bank Of America Corp /de/ | 136,248 | $2M | New | Mar 2026 |
| 13 | Citadel Advisors Llc | 135,278 | $2M | Reduced | Jun 2026 |
| 14 | Yakira Capital Management, Inc. | 133,047 | $2M | Added | Jun 2026 |
| 15 | Tudor Investment Corp Et Al | 129,591 | $2M | Added | Jun 2026 |
| 16 | Norges Bank | 126,575 | $2M | New | Jun 2026 |
| 17 | Trium Capital Llp | 113,278 | $2M | New | Jun 2026 |
| 18 | Td Asset Management Inc | 111,200 | $1M | New | Jun 2026 |
| 19 | Athos Capital Ltd | 107,965 | $1M | — | Jun 2026 |
| 20 | Vanguard Portfolio Management Llc | 101,195 | $1M | Reduced | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$157.7M
Enterprise Value
-$112.2M
P/E (TTM)
-2.06x
Forward P/E
—
PEG Ratio
0.00x
P/B
0.76x
P/S
8.48x
P/FCF
-3.71x
EV/EBITDA
—
Shares Out
17.1M
Financials (TTM)
Revenue
$18.6M
Net Income
-$76.7M
EBITDA
-$76.5M
Free Cash Flow
-$42.6M
Op Cash Flow
-$41.1M
EPS Basic
$-4.48
EPS Diluted
$-4.48
EPS Forward
$-5.04
Gross Margin
100.0%
Op Margin
-412.6%
Net Margin
-411.9%
Balance Sheet
Total Assets
$278.4M
Total Liab.
$71.1M
Total Equity
$207.3M
Cash
$270.0M
LT Debt
$0
Book Value/Sh
$12.11
Debt/Equity
0.02x
Current Ratio
6.53
Quick Ratio
6.53
Returns & Growth
ROE
-40.5%
ROA
-35.0%
ROIC
-31.9%
Rev Growth YoY
+0.0%
EPS Growth YoY
—
Price Returns
2W
-18.8%
1M
-30.2%
3M
-28.0%
6M
-30.2%
12M
-37.5%
Technicals
52W High
$16.77
52W Low
$8.66
50d MA
$12.08
200d MA
$12.88
RSI (14)
17.00
ATR (14)
$0.76
Beta
0.00
Avg Volume
310K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 11:11pm
· Source: financialmodelingprep.com